Business Moderna’s unlikely journey to rivaling Big Pharma giants’ valuations Published 3 years ago on 6 August 2021 By Terry Power Boosted by the COVID vaccine, Moderna’s valuation has now leapfrogged that of well-established Big Pharma giants like Bristol Myers Squibb and Sanofi. Can it last? Read More Related Topics:bigbristol myers squibb valuationCOVIDcovid vaccineCOVID-19giantsJourneyModernamoderna covidmoderna covid boostermoderna covid booster shotmoderna covid vaccinemoderna covid vaccine delta variantmoderna covid vaccine salesmoderna delta variant boostermoderna earningsmoderna earnings reportmoderna market capmoderna market valuemoderna sharesmoderna stockmoderna vaccine delta variantmoderna vaccine salesmoderna valuationModernasPharmarivalingsanofi valuationvaluations